Cargando…
A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells
PURPOSE: Glioblastoma (GBM) is the commonest brain tumour in adults. A sub-population of cells within these tumours, known as cancer stem cells (CSCs), is thought to mediate their chemo-/radiotherapy resistance. CD133 is a cell surface marker that is used to identify and isolate GBM CSCs. However, i...
Autores principales: | Ahmed, Eroje M., Bandopadhyay, Gagori, Coyle, Beth, Grabowska, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951876/ https://www.ncbi.nlm.nih.gov/pubmed/29492900 http://dx.doi.org/10.1007/s13402-018-0374-8 |
Ejemplares similares
-
A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia
por: Musah-Eroje, Ahmed, et al.
Publicado: (2019) -
CD133 Expression in Glioblastoma Multiforme: A Literature Review
por: Ahmed, Syed Ijlal, et al.
Publicado: (2018) -
An Overview of CD133 as a Functional Unit of Prognosis and Treatment Resistance in Glioblastoma
por: Joyce, Thomas, et al.
Publicado: (2023) -
Adaptive Changes of Glioblastoma Cells Following Exposure to Hypoxic (1% Oxygen) Tumour Microenvironment
por: Musah-Eroje, Ahmed, et al.
Publicado: (2019) -
Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting
PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer
Cells
por: Lu, Ruiqi, et al.
Publicado: (2019)